Entropy Technologies LP Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Entropy Technologies LP lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 121.9% during the first quarter, HoldingsChannel reports. The firm owned 35,719 shares of the biopharmaceutical company’s stock after purchasing an additional 19,622 shares during the quarter. Entropy Technologies LP’s holdings in Alnylam Pharmaceuticals were worth $11,818,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Norges Bank acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $895,816,000. Qube Research & Technologies Ltd purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth $369,943,000. AQR Capital Management LLC lifted its holdings in Alnylam Pharmaceuticals by 295.2% in the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock worth $336,009,000 after buying an additional 555,759 shares in the last quarter. Orbis Allan Gray Ltd lifted its holdings in Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after buying an additional 486,489 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its position in Alnylam Pharmaceuticals by 2,221.7% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 410,342 shares of the biopharmaceutical company’s stock valued at $187,116,000 after buying an additional 392,668 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ALNY has been the subject of several recent analyst reports. JPMorgan Chase & Co. lowered their target price on Alnylam Pharmaceuticals from $420.00 to $400.00 and set an “overweight” rating for the company in a research note on Wednesday. Bank of America cut their price target on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. Wall Street Zen raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Morgan Stanley raised their price objective on Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the company an “equal weight” rating in a research note on Friday, July 10th. Finally, Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $452.13.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $271.77 on Friday. The firm has a fifty day moving average of $292.22 and a two-hundred day moving average of $316.64. The firm has a market cap of $36.28 billion, a P/E ratio of 74.25 and a beta of 0.27. Alnylam Pharmaceuticals, Inc. has a 1-year low of $262.21 and a 1-year high of $495.55. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the business posted ($0.44) EPS. The company’s revenue for the quarter was up 96.4% on a year-over-year basis. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.35 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.